Oncology Programs
We have two oncology compounds, rhIGFBP-3 and INSM-18, in early development and both hold promise for the potential treatment for a variety of cancers.
Preclinical models show that one or both treatments interact with the IGF-1 system to reduce tumor growth in models of breast, prostate, lung, colorectal and head and neck cancers. Although the oncology platform shows promise, the company's resources will be focused primarily on ARIKACE and the Company intends that any further clinical trials in the oncology area will be conducted either with a partner or potentially throughout licensing. Insmed has already out licensed INSM 18 in both oncology (to TriAct) and diabetes (to NAPO Pharmaceuticals Inc.)
